Rhythm Pharmaceuticals surges after FDA approval of obesity drug
IMCIVREE becomes first-ever therapy for acquired hypothalamic obesity, expanding addressable market
Rhythm Pharmaceuticals shares jumped more than 5% on Wednesday after the U.S. Food and Drug Administration approved an expanded use of its obesity drug IMCIVREE, marking the first-ever therapy for a rare form of weight gain caused by brain injury.
The stock gained 5.2% to close at $90.31, with trading volume surging to 27 million shares, significantly above its daily average. The rally lifted the company's market capitalization to $5.86 billion.
The FDA approval covers acquired hypothalamic obesity, a rare disease characterized by accelerated and sustained weight gain resulting from damage to the hypothalamus—the brain region regulating hunger and metabolism. The condition affects approximately 10,000 people in the United States, according to the company's estimates.
"IMCIVREE is now the first and only FDA-approved therapy for acquired HO, offering a targeted approach that addresses the underlying biology of this disease and meets a critical unmet need for patients who previously had no treatment options," said David Meeker, Rhythm's chairman and chief executive officer.
The approval was based on positive results from the pivotal Phase 3 TRANSCEND trial, which enrolled 142 patients. The study demonstrated a statistically significant 18.4% placebo-adjusted reduction in body mass index at 52 weeks. Patients treated with setmelanotide achieved a 15.8% reduction in BMI from baseline, compared to a 2.6% increase for those receiving placebo.
Analysts project the expanded indication could generate "several hundred million dollars" in additional annual revenue for the Boston-based biopharmaceutical company. IMCIVREE is already approved in the United States and Europe for certain genetic forms of obesity, including Bardet-Biedl syndrome and deficiencies in specific genes involved in appetite regulation.
The company reported $189.8 million in trailing twelve-month revenue, representing 36.9% year-over-year growth. Rhythm remains unprofitable, with losses of $3.11 per share over the past year, as the company invests in commercial expansion and clinical development.
Wall Street analysts remain broadly optimistic about Rhythm's prospects. The consensus price target stands at $135.53, representing roughly 50% upside from current levels, according to market data. Of 16 analysts covering the stock, 15 rate it a buy or strong buy, with one holding a neutral rating.
Rhythm's shares remain well below their 52-week high of $122.20 set earlier this year, having retreated from those levels as investors rotated out of biotechnology stocks. The stock remains above its 200-day moving average of $95.94, however, indicating continued positive momentum.
Acquired hypothalamic obesity typically develops following brain tumors, radiation treatment, head trauma, or other damage to the hypothalamus. The condition causes patients to experience relentless hunger and inability to feel full, leading to rapid and difficult-to-control weight gain.
"Having a therapy for individuals and families affected by acquired hypothalamic obesity has the potential to be transformational," said Amy Wood, executive director of the Raymond A. Wood Foundation, an organization focused on hypothalamic-pituitary conditions. "We've seen firsthand the devastating impact acquired HO has on patients' and families' lives. IMCIVREE offers hope and a path forward for thousands of patients who have long been without options."
The most common side effects observed in clinical trials included skin hyperpigmentation, nausea, vomiting, and headache, affecting more than 20% of participants. The drug is now indicated for adults and pediatric patients aged four years and older.
Rhythm Pharmaceuticals, founded in 2008, focuses on developing therapies for rare genetic diseases of obesity. The company's strategy centers on targeting the MC4R pathway, a critical biological system involved in regulating appetite and weight.